Type 1 diabetes patients are required to take insulin injections to maintain their blood sugar. Insulin doses are required several times in a day and in some cases more than one type of insulin is required. But now a new discovery claims to do the work of insulin.
Researchers led by the University of Adelaide have found how potential anti-diabetic drugs interact with their target in the body at the molecular level.
"Type two diabetes is characterized by resistance to insulin with subsequent high blood sugar which leads to serious disease. It is usually associated with poor lifestyle factors such as diet and lack of exercise," said John Bruning, from University of Adelaide.
Most commonly prescribed anti-diabetes drugs like Metformin act on the liver in order to reduce the glucose product but this is not the case with the new drug. The new drug targets aprotein receptor known as PPARgamma. The protein receptor is found in fat tissue throughout the body, either fully or partially activating it to lower the blood sugar levels by increasing sensitivity to insulin and also altering the metabolism of fat and sugar.
"People with severe diabetes need to take insulin but having to inject this can be problematic, and it's difficult to get insulin levels just right," said Bruning.